| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BioLife Solns (NASDAQ:BLFS) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
BioLife Solns beat estimated earnings by 38.0%, reporting an EPS of $-0.21 versus an estimate of $-0.34.
Revenue was down $11.53 million from the same period last year.
Last quarter the company beat on EPS by $0.05 which was followed by a 4.0% drop in the share price the next day.
Here's a look at BioLife Solns's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.38 | -0.20 | -0.21 | -0.17 |
| EPS Actual | -0.33 | -0.24 | -0.27 | -0.19 |
| Revenue Estimate | 32.94M | 43.86M | 42.94M | 43.28M |
| Revenue Actual | 33.33M | 39.51M | 37.70M | 44.26M |
To track all earnings releases for BioLife Solns visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BLFS
